Illumina (NASDAQ:ILMN) PT Raised to $135.00

Illumina (NASDAQ:ILMN) had its price target upped by Barclays from $125.00 to $135.00 in a research report report published on Tuesday, Benzinga reports. They currently have an equal weight rating on the life sciences company’s stock.

Several other brokerages have also recently commented on ILMN. Argus upgraded shares of Illumina from a hold rating to a buy rating and set a $150.00 price target on the stock in a research note on Wednesday, August 28th. Stephens reiterated an overweight rating and issued a $170.00 price target on shares of Illumina in a research note on Wednesday, July 10th. Daiwa America upgraded shares of Illumina to a strong-buy rating in a report on Friday, August 16th. Daiwa Capital Markets upgraded shares of Illumina from a neutral rating to a buy rating and boosted their target price for the stock from $120.00 to $154.00 in a report on Friday, August 16th. Finally, Piper Sandler reduced their target price on shares of Illumina from $200.00 to $195.00 and set an overweight rating on the stock in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina presently has a consensus rating of Moderate Buy and a consensus target price of $150.58.

Illumina Stock Down 1.0 %

ILMN opened at $147.61 on Tuesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $151.40. The firm’s fifty day moving average is $131.49 and its 200 day moving average is $120.79. The stock has a market cap of $23.51 billion, a price-to-earnings ratio of -18.11 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 EPS. On average, sell-side analysts forecast that Illumina will post 3.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Several large investors have recently added to or reduced their stakes in ILMN. Primecap Management Co. CA boosted its position in Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after buying an additional 1,997,010 shares during the period. Millennium Management LLC boosted its position in Illumina by 305.0% in the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares during the period. Capital World Investors boosted its position in Illumina by 41.1% in the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after buying an additional 801,814 shares during the period. Marshall Wace LLP purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $77,628,000. Finally, Findlay Park Partners LLP purchased a new stake in shares of Illumina in the 1st quarter worth approximately $100,120,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.